VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | frontMIND: Tafasitamab + lenalidomide + R-CHOP vs R-CHOP in high-intermediate & high-risk DLBCL

In this video, Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses the rationale behind the ongoing Phase III frontMIND trial (NCT04824092), which is evaluating the safety and efficacy of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP alone in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter